## Clinical Context This patient presents with classic symptoms and biochemical findings of primary hypothyroidism: elevated TSH with low-normal free T4, consistent with early overt hypothyroidism. ## Management Approach **Key Point:** In overt hypothyroidism with clear clinical and biochemical evidence, treatment initiation should not be delayed by further antibody testing or imaging in the absence of nodules or malignancy risk. **High-Yield:** The diagnosis of primary hypothyroidism is established by the combination of: - Elevated TSH (>4.0 mIU/L) - Low or low-normal free T4 - Compatible clinical symptoms ## Rationale for Correct Answer Starting levothyroxine at a low dose (50 mcg daily) with TSH reassessment in 6–8 weeks is the standard approach for: - Newly diagnosed overt hypothyroidism in a middle-aged patient without cardiac comorbidities - Avoiding over-replacement and iatrogenic hyperthyroidism - Allowing steady-state achievement before dose titration **Clinical Pearl:** The standard starting dose in non-elderly, non-cardiac patients is 25–50 mcg daily. A 6–8 week interval allows the TSH to reach a new steady state (levothyroxine half-life ~7 days). ## Why Antibody Testing Is Not the Next Step Anti-TPO and anti-thyroglobulin antibodies: - Confirm autoimmune etiology (Hashimoto thyroiditis) but do NOT change immediate management - Can be checked at baseline or deferred; their absence does not exclude autoimmune disease - Should not delay treatment initiation in symptomatic overt hypothyroidism **Tip:** Antibody testing is useful for prognostication and counseling (risk of other autoimmune conditions, family screening) but is not a prerequisite for starting therapy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.